Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis

被引:8
|
作者
Zhang, Qiang [1 ]
Qi, Zhijiang [1 ]
Bo-Liu [1 ]
Li, Chun-Sheng [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Beijing Key Lab Cardiopulm Cerebral Resuscitat, Beijing 100020, Peoples R China
关键词
INDUCED IMMUNOSUPPRESSION; ANTI-PD-L1; ANTIBODY; ADVANCED CANCER; EXPRESSION; PD-1; MORTALITY; IMMUNOTHERAPY; INCREASES; INFECTION; DISEASES;
D O I
10.1155/2018/1969474
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Object. To investigate effects of programmed cell death-1 (PD-1) related blockade in sepsis animals. Methods. Two reviewers independently searched electronic databases including PubMed, EMBASE, and the Cochrane Library up to February 2017. Strict literature retrieval and data extraction were performed to extract relevant data. Data analysis was conducted using RevMan 5.3 software and Stata version 12.0. And relative risks (RRs) for survival rate were calculated. A fixed-effect model was selected to pool and a forest plot was used to display RRs. Results. Four studies involving 394 animals were finally included. Nine control groups are used to pool. A fixed-effect model was applied to estimate a pooled RR of 2.19 (95% CI: 1.74-2.76), indicating that PD-1 related blockade increased survival rate in sepsis animals. Conclusion. We concluded that PD-1 related blockade can improve survival of animals with sepsis. But robust standardized clinical experiments for sepsis patients are highly desirable.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] SAR study of small molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction
    Kawashita, Seiji
    Aoyagi, Koichi
    Fukushima, Kyoko
    Hantani, Rie
    Naruoka, Shiori
    Tanimoto, Atsuo
    Hori, Yuji
    Toyonaga, Yukiyo
    Yamanaka, Hiroshi
    Miyazaki, Susumu
    Hantani, Yoshiji
    CHEMICAL BIOLOGY & DRUG DESIGN, 2021, 98 (05) : 914 - 929
  • [22] Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
    Guo, Jhe-Cyuan
    Tsai, Yu-Chieh
    Pu, Yeong-Shiau
    UROLOGICAL SCIENCE, 2019, 30 (01) : 2 - 7
  • [23] Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis
    Santoni, Matteo
    Conti, Alessandro
    Buti, Sebastiano
    Bersanelli, Melissa
    Foghini, Laura
    Piva, Francesco
    Giulietti, Matteo
    Lusuardi, Lukas
    Battelli, Nicola
    IMMUNOTHERAPY, 2018, 10 (15) : 1303 - 1314
  • [24] Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma
    Montasser, Ahmed
    Beaufrere, Aurelie
    Cauchy, Francois
    Bouattour, Mohamed
    Soubrane, Olivier
    Albuquerque, Miguel
    Paradis, Valerie
    HISTOPATHOLOGY, 2021, 79 (01) : 36 - 46
  • [25] Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
    Goto, Hiroyuki
    Sugita, Kazunari
    Yamamoto, Osamu
    INDIAN JOURNAL OF DERMATOLOGY, 2021, 66 (02) : 169 - 173
  • [26] Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
    Chen, Kaiyan
    Cheng, Guoping
    Zhang, Fanrong
    Zhang, Nan
    Li, Dan
    Jin, Jiaoyue
    Wu, Junzhou
    Ying, Lisha
    Mao, Weimin
    Su, Dan
    ONCOTARGET, 2016, 7 (21) : 30772 - 30780
  • [27] Rare Adverse Events with Programmed Death-1 and Programmed Death-1 Ligand Inhibitors: Justification and Rationale for a Systematic Review
    Smith, Caleb J.
    Almodallal, Yahya
    Jatoi, Aminah
    CURRENT ONCOLOGY REPORTS, 2021, 23 (07)
  • [28] Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
    Zhu, Zhenhua
    Jin, Zheng
    Zhang, Mei
    Tang, Yajun
    Yang, Guang
    Yuan, Xiaowei
    Yao, Jihang
    Sun, Dahui
    ONCOTARGET, 2017, 8 (35) : 59570 - 59580
  • [29] Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review
    Choi, Franchesca D.
    Kraus, Christina N.
    Elsensohn, Ashley N.
    Carley, Sama K.
    Lehmer, Larisa M.
    Nguyen, Rebecca T.
    Linden, Kenneth G.
    Shiu, Jessica
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 440 - 459
  • [30] Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma
    Tagliamento, Marco
    Di Maio, Massimo
    Remon, Jordi
    Bironzo, Paolo
    Genova, Carlo
    Facchinetti, Francesco
    Aldea, Mihaela
    Le Pechoux, Cecile
    Novello, Silvia
    Barlesi, Fabrice
    Besse, Benjamin
    Planchard, David
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (01) : 166 - 172